Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Ovarian Cancer, monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
Last updated October 21, 2020
Status:
Concluded with an LOI
Manufacturer:
Alexion Pharma GmbH
Indication:
Lysosomal acid lipase deficiency
Last updated October 21, 2020
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Multiple Indications
Last updated October 14, 2020
Contrave (naltrexone hydrochloride and bupropion hydrochloride)
Status:
Negotiations were not pursued
Manufacturer:
Bausch Health, Canada Inc.
Indication:
Chronic weight management
Last updated October 13, 2020
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated September 30, 2020
Adcetris (brentuximab vedotin)
Status:
Concluded with an LOI
Manufacturer:
Seattle Genetics Inc.
Indication:
Peripheral T-cell Lymphoma (PTCL)
Last updated September 21, 2020
Tecentriq & Avastin (Atezolizumab & Bevacizumab)
Status:
Negotiations were not pursued
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Non-Squamous Non-Small Cell Lung Cancer
Last updated September 1, 2020
Mylotarg (gemtuzumab ozogamicin)
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Acute Myeloid Leukemia (AML)
Last updated August 12, 2020
Status:
Concluded with an LOI
Manufacturer:
Paladin Labs Inc.
Indication:
Prophylaxis of Organ Rejection in Allogenic Kidney or Liver Transplant Adult Patients
Last updated July 30, 2020
Lutathera (lutetium 177 dotatate)
Status:
Concluded with an LOI
Manufacturer:
Advanced Accelerator Applications
Indication:
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Last updated July 29, 2020